Please provide your email address to receive an email when new articles are posted on . Patients with pulmonary arterial hypertension at intermediate risk who switched from phosphodiesterase type 5 ...

Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...

The most common ED medications are PDE5 inhibitors. These work by enhancing nitric oxide effects to relax muscles in the penis, increase blood flow, and facilitate erections in response to sexual ...

Boston, MA — December 18, 2025 — A research-driven evaluation assessing the comparative effectiveness of phosphodiesterase type 5 (PDE5) inhibitors is contributing to ongoing clinical discourse around ...

The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than ...

The management of erectile dysfunction (ED) has been revolutionized by the discovery of phosphodiesterase 5 (PDE5) inhibitors, which have been commercially available for more than a decade and are the ...

To date, benign diseases of the male and female lower urinary and genital tract, such as erectile dysfunction, bladder overactivity, lower urinary tract symptomatology secondary to benign prostatic ...

Phosphodiesterase 5 (PDE5) inhibitors (eg, sildenafil, tadalafil) do not appear to reduce the risk of Alzheimer disease and related dementias, according to a National Institutes of Health (NIH) study.

SAN FRANCISCO, CA—Phosphodiesterase 5 (PDE5) inhibitors appear to be effective in treating Raynaud’s phenomenon secondary to scleroderma, investigators concluded at the 2015 ACR/ARHP Annual Meeting.

Some erectile dysfunction (ED) treatments could be beneficial for a person recovering from a heart attack because they help lower blood pressure. However, people should wait 24–48 hours to take ...